BioCentury
ARTICLE | Company News

Roche sales and marketing update

September 19, 2016 7:00 AM UTC

The U.K.’s NICE issued draft guidance recommending against the use of Gazyvaro obinutuzumab from Roche in combination with Treanda bendamustine followed by Gazyvaro maintenance therapy to treat foll...